The Latest Breaking News from Cancer

Faith revealed her cancer had returned and was terminal, causing an argument

Gareth Lyon is taking on a 4,000 mile cycle to raise money and awareness for Prostate Cancer UK - and he's being joined by volunteers along the way for legs of his journey

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price.  The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies.  But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

David Tennant's wife Georgia previously opened up about her experience having a cervical screening and then, later, a colposcopy

BMO Capital Markets initiated the coverage on Precision BioSciences Inc (NASDAQ:DTIL) with an Outperform rating and a price target of $7. The analyst said the thesis is based on: The company's proprietary gene-editing platform, whose mechanism is differentiated in a CRISPR-dominated space, offers several advantages. A diversified pipeline. Asymmetric risk/reward skewed to the upside.…

Organiser Edel Moore launched a fundraiser on GoFundMe for the family of 10-year-old Bridget Hynes earlier this month

Here's a roundup of top developments in the biotech space over the last 24 hours:

“You really don’t know how strong you are until being strong is your only option.”

Exclusive: experts believe new form of photoimmunotherapy may become fifth major cancer treatment

The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ: KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer.

Abemaciclib is a twice-daily pill that is used with hormone therapy